How cholesterol travels in the blood: LDL, HDL, and ApoB

Why cholesterol needs a delivery system

Cholesterol is a lipid — a fat-like molecule the body uses as a building block for cell membranes and as a raw material for making certain hormones, vitamin D, and the bile acids that help digest fats. Like other lipids, cholesterol does not dissolve in water. Blood plasma, the fluid that carries substances around the body, is mostly water. This creates a basic transport problem: a fatty molecule cannot simply float freely through a watery medium and reach the tissues that need it.

The body's solution is to package cholesterol, along with triglycerides (another type of fat), inside tiny spherical particles called lipoproteins. As the name suggests, these are combinations of lipid and protein. The protein and other surface components give each particle a water-friendly outer coat, so the fatty cargo can be shuttled through the bloodstream without separating out. Lipoproteins are, in effect, the delivery vehicles for cholesterol and other fats — the reason terms like LDL and HDL come up at all is that they are names for different classes of these particles.

This article is educational and describes how the body is understood to transport cholesterol at the level of biology. It does not diagnose anything, does not make claims about any medication or supplement, provides no dosing, and is not a substitute for guidance from a licensed clinician. Understanding how the transport system works is useful background, but what it means for any individual is a clinical question a provider answers, not something an article can determine.

What a lipoprotein particle is made of

A lipoprotein is usually described as a roughly spherical particle with a core and a shell. The inner core holds the water-repelling cargo: mainly cholesteryl esters (cholesterol joined to a fatty acid) and triglycerides, both of which are hydrophobic and prefer to stay away from water. Wrapped around this core is an outer shell built from phospholipids and a modest amount of free, unesterified cholesterol, arranged with their water-friendly faces pointing outward. Embedded in that shell are specialized proteins called apolipoproteins, which are central to the rest of this story.

Lipoproteins are not all the same. They are traditionally sorted into a family of classes by their density — a property that reflects how much lipid versus protein a particle carries, and historically measured by spinning blood in an ultracentrifuge. More lipid and less protein makes a particle larger and less dense; more protein makes it smaller and denser. From least dense to most dense, the main classes are chylomicrons, very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL).

Each class tends to play a characteristic role:

• Chylomicrons are described as the large particles the intestine assembles to carry dietary fat after a meal.
• VLDL is described as the particle the liver secretes to export triglycerides it has made.
• IDL and LDL are described as what VLDL becomes as it delivers its triglyceride cargo, with LDL being comparatively rich in cholesterol.
• HDL, the smallest and densest class, is described as central to a return pathway discussed later in this guide.

Naming the family this way sets up the key point that the same molecule — cholesterol — travels in several different vehicles depending on where it is going.

What apolipoproteins like ApoB mark

The proteins studded into a lipoprotein's shell are called apolipoproteins, and they do more than hold the particle together. Depending on the type, an apolipoprotein can act as a structural scaffold that keeps the particle stable, as a ligand — a molecular tag that a cell-surface receptor recognizes and grabs onto — or as a cofactor that activates enzymes involved in lipid handling. In other words, apolipoproteins are part of the addressing and routing system that decides where a particle's cargo goes.

Apolipoprotein B, or ApoB, is the defining structural protein of the particles on the liver-to-tissue delivery side of the system. It comes in two related forms: ApoB-100, which the liver places on VLDL, IDL, and LDL, and ApoB-48, a shortened version the intestine places on chylomicrons. A frequently noted feature is that each of these particles carries exactly one ApoB molecule, and that molecule stays with the particle throughout its life rather than being swapped between particles. Because of this one-per-particle rule, ApoB is described as a marker of the number of these particles present, distinct from the amount of cholesterol they happen to be carrying.

ApoB-100 also serves as the recognition tag for a specific receptor. The LDL receptor on the surface of liver and other cells is understood to recognize and bind ApoB-100, which is the step that lets a cell pull an LDL particle out of the blood and take up its cholesterol. HDL, by contrast, is built around a different lead protein, apolipoprotein A-I (ApoA-I), which is described as its main structural apolipoprotein and as a participant in the return pathway. So the apolipoprotein a particle carries is a strong clue to which route it belongs to: ApoB marks the delivery-side particles, while ApoA-I marks HDL.

The forward route: delivering cholesterol to tissues

The outbound, or forward, direction of cholesterol traffic begins largely in the liver. The liver assembles VLDL particles and secretes them into the bloodstream loaded with triglycerides and cholesterol, each carrying a single ApoB-100. As a VLDL particle circulates, an enzyme anchored to the walls of small blood vessels, called lipoprotein lipase, is understood to remove triglycerides from its core so nearby tissues can use them for energy or storage. As the particle sheds triglyceride, it shrinks and grows denser, converting first into IDL and then into LDL — a particle that is now comparatively rich in cholesterol. This is why LDL is often described as the principal cholesterol-carrying particle of the delivery route.

LDL then circulates and can deliver cholesterol where it is needed. The main way cholesterol is understood to leave an LDL particle and enter a cell is through the LDL receptor. That receptor binds the particle's ApoB-100 tag, and the particle is drawn into the cell in a process called receptor-mediated endocytosis, where its cholesterol is released for the cell to use in membranes and other functions. The liver carries large numbers of LDL receptors and is understood to be a major site where LDL is cleared from the blood in this way.

How many LDL receptors a liver cell displays is itself regulated by how much cholesterol the cell senses inside. When a cell's internal cholesterol runs low, a signaling system involving proteins called SREBPs is understood to prompt it to place more LDL receptors on its surface, increasing its capacity to take LDL up from the blood; when the cell has ample cholesterol, it displays fewer. This feedback loop is a well-studied piece of cholesterol biology and is the mechanism several cholesterol-related medications are described as acting through, a topic covered in separate guides. Here it simply illustrates that the forward route is actively controlled, not passive.

The reverse route: reverse cholesterol transport and HDL

Delivery is only half of the system. Cells throughout the body can end up with more cholesterol than they need, and there is a route understood to carry excess cholesterol from peripheral tissues back toward the liver, where it can be repurposed or removed from the body. This return pathway is called reverse cholesterol transport, and HDL is the class of particle described as central to it. The word 'reverse' captures the direction: away from the tissues and back to the liver, opposite to the outbound LDL route.

Reverse cholesterol transport is understood to begin with small, relatively protein-heavy HDL particles built around ApoA-I. A cell-surface transporter called ABCA1 is understood to move free cholesterol out of cells — including from macrophages, immune cells that can accumulate cholesterol — and onto these ApoA-I-bearing particles, a step known as cholesterol efflux. An enzyme carried on HDL, lecithin–cholesterol acyltransferase (LCAT), is then understood to convert the free cholesterol into cholesteryl ester, which migrates into the particle's core. As it takes on this cargo, the small nascent HDL matures into a larger, more spherical particle.

From there, the cholesterol HDL has collected is understood to reach the liver by more than one path. HDL can dock at a liver receptor called SR-BI, which is understood to allow the liver to take up cholesteryl esters from the particle in a selective way. Alternatively, a transfer protein called cholesteryl ester transfer protein (CETP) is understood to shuttle cholesteryl esters from HDL onto ApoB-containing particles such as VLDL and LDL, which the liver can then clear through the LDL receptor. Once cholesterol arrives at the liver, it can be secreted into bile — directly or after conversion into bile acids — which is described as the body's main route for eliminating cholesterol. This whole return circuit is the reverse-transport mechanism researchers study when they describe HDL's role.

How this is measured, and who decides what it means

The two directions of traffic explain why blood tests describe cholesterol in more than one way. A standard lipid panel reports concentrations — for instance, the amount of cholesterol carried within LDL particles (often written as LDL-C) and within HDL particles (HDL-C). These are measures of how much cholesterol is present in each class. Because ApoB appears once per delivery-side particle, an ApoB measurement is instead described as an estimate of the number of those particles. Researchers note that the amount of cholesterol and the number of particles do not always move together, and they use the term discordance for situations where the two measures disagree. These are descriptions of what the tests represent, not statements about any individual's health.

It is worth being precise about what this biology does and does not establish. Describing LDL as a delivery particle and HDL as central to a return pathway is a mechanistic picture; it is not a verdict on any person, and popular shorthand like 'good' and 'bad' cholesterol oversimplifies a system in which the same molecule travels in different vehicles for different purposes. Nothing in this article should be read as a claim that any particular number, particle, or pathway causes or prevents an outcome in a specific individual, or that any product changes it.

This guide is educational and is not medical advice. It does not diagnose any condition, interpret anyone's lab results, or recommend any medication, supplement, or course of action. Interpreting lipoproteins and apolipoproteins in the context of a real person — alongside their history, other measures, and overall picture — is a clinical judgment that belongs to an independent licensed provider. On OpenDoseRx, every product is prescription-only: a person requests a product and completes a medical intake, an independent licensed U.S. provider reviews it and decides whether a prescription is appropriate, and only then does a licensed U.S. pharmacy dispense it; if a request is declined, the medication is not charged and is refunded. Where a product is a compounded preparation, it is not an FDA-approved drug, and statements about it have not been evaluated by the FDA. Use this guide to understand the biology, and bring your questions to the clinician who reviews your intake or to your own healthcare provider.